{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"1x10\\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.\n\nE7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\\^11 cells) will be administered intravenously over 20 to 30 minutes.","id":"OG000","title":"Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 months","title":"Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment","type":"PRIMARY","unitOfMeasure":"Proportion of participants"}